Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
erythromycin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Single Dose Pregabalin Controlled Release |
| 2 | EXPERIMENTAL | Single Dose Pregabalin Controlled Release with Multiple Doses of Erythromycin |
| Name | Type | Description |
|---|---|---|
| Pregabalin controlled release, 330 mg | DRUG | A single oral dose of 330 mg controlled release tablet |
| erythromycin | DRUG | A total of three doses of 500 mg erythromycin ethylsuccinate tablets administered six hours apart beginning approximately 1 hour prior to pregabalin CR |
Inclusion Criteria: * Healthy male or females * Between the ages of 18 and 55 years, inclusive * Body Mass Index (BMI) of 17.5 to 30.5 kg/m2 Exclusion Criteria: * Illicit drug use * Pregnant or nursing females * Females of childbearing potential who are unwilling or unable to use an acceptable me...
Erythromycin is a small molecule being studied in healthy volunteers. It is being investigated for its effects on the pharmacokinetics of pregabalin controlled release tablets. The drug is currently in Phase 1 clinical development and is not approved for any indication.
Erythromycin is being developed by Pfizer, Inc. (NYSE: PFE). The company is conducting clinical trials to evaluate the drug's effects in healthy volunteers.
Erythromycin is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The completed Phase 1 trial involved 18 healthy participants.
Erythromycin has one completed clinical trial, NCT01342198, titled "An Investigation of the Effects of Erythromycin on the Pharmacokinetics of the Pregabalin Controlled Release Tablet." This Phase 1 study enrolled 18 healthy volunteers in Belgium.
No, erythromycin is not the same as pregabalin. Erythromycin is the investigational drug being studied, while pregabalin is the medication whose pharmacokinetics are being examined in the clinical trial. The study investigates how erythromycin affects the absorption and processing of pregabalin controlled release tablets.